A phase I evaluation of oral CI-1033 [canertinib] in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer

Trial Profile

A phase I evaluation of oral CI-1033 [canertinib] in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2006

At a glance

  • Drugs Canertinib; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Aug 2006 Status change
    • 19 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top